PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infection caused by Staphylococcus aureus (S. aureus). Endocarditis is an infection of the endocardium (inner lining of the…
Groundbreaking Study by Dr. Agarwal’s Eye Hospital on post-crosslinking surgery patients Wins ‘Best Scientific Poster Award’ at ASCRS 2024 Annual Meeting
Dr Agarwal’s Eye Hospital recently announced that their accomplished research team have been honoured with the prestigious ‘Best Scientific Poster Award’ at the 2024 Annual Meeting of the American Society for Cataract and Refractive Surgery (ASCRS). This recognition comes in…
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe™ Device at NPIAP 2024 Annual Conference on February 16
IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial intelligence (AI) driven spectrographic analysis technology platform to address significant healthcare needs, announced today that final data from a study conducted at two medical centers, Beit Rivka Hospital,…
Endovascular Engineering’s Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism
Endovascular Engineering (“E2”), a medical device company focused on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE), announced today FDA Investigational Device Exemption (IDE) approval for its ENGULF US pivotal trial. This study will…
SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2023 San Antonio Breast Cancer Conference and US Clinical Trial Developments
SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC, BL-M07D1, in the Investigational New Drug (IND) application…
Agilus Diagnostics publishes data study ahead of World Diabetes Day 2023
India has emerged as the diabetes capital of the world with incidence steadily on the rise over the last three decades. The prevalence of diabetes in India stood at 8.9% in 2019 with more than 77 million people with diabetes….
First patient treated in the second dose group in Annexin’s RVO study
Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company’s clinical phase 2 study in patients with retinal vein occlusion (RVO) with the investigational drug candidate ANXV. No…
Clinical Study Conducted at Medical University of South Carolina Finds Synchrony Medical’s LibAirty™ Airway Clearance System Highly Effective for Chronic Lung Disease Patients
The results of a clinical study of Synchrony Medical’s LibAirty™ Airway Clearance System showed that the system was twice as effective in clearing mucus from the lungs of patients with chronic lung disease when compared to the standard of care therapy….
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
ALR Technologies SG Ltd. (“ALRT” or the “Company”) (OTCQB: ALRTF), a diabetes management company, announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan (“Predictive A1c”) has been granted in Singapore and has received notice of…
Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs containing fluorouracil and platinum for the…
